Vascular endothelial growth factor receptor 2 (VEGFR2)

Overview

KDR, also known as Kinase Insert Domain-containing Receptor or VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), is a receptor tyrosine kinase that plays a critical role in vascular development and angiogenesis. As a primary mediator of VEGF signaling in endothelial cells, KDR is essential for the formation and maintenance of blood vessels. Beyond its physiological role in normal angiogenesis, dysregulation of KDR signaling has been implicated in various pathological conditions, including solid tumors, where aberrant angiogenesis supports tumor growth and metastasis. Consequently, KDR has emerged as a significant pharmaceutical target, with multiple tyrosine kinase inhibitors (TKIs) designed to selectively or broadly inhibit KDR and related VEGF receptors (such as VEGFR1 and VEGFR3) to impede tumor-associated neovascularization. This receptor represents a cornerstone target in modern oncology and has expanded into other therapeutic areas where pathological angiogenesis plays a pathogenic role.

Recent Publications Summary

Recent publications on Vascular endothelial growth factor receptor 2 (VEGFR2) have continued to focus on its central role in angiogenesis and as a therapeutic target in cancer and neovascular disease. Several studies described the design and evaluation of new small-molecule VEGFR2 inhibitors, often using quinazoline, indolin-2-one, pyrazole, chalcone, or oxadiazole scaffolds, with in silico docking, molecular dynamics, and ADMET analyses used to support target engagement and drug-likeness 42208487May41936795Apr41903478Mar41785707Mar41621723Feb41563668Jan. These compounds generally showed antiproliferative, antiangiogenic, and pro-apoptotic activity in cancer cell models, with some exhibiting VEGFR2 inhibition comparable to or better than reference agents such as sorafenib 41936795Apr41785707Mar41621723Feb41563668Jan.

Beyond oncology, VEGFR2 was also targeted in neovascular glaucoma research. A dual-functional inhibitor, H24, was reported to inhibit VEGFR2, PDGFRα/β, and carbonic anhydrase II, with activity in VEGFR2-BAF3 cells, HUVEC angiogenesis assays, and rabbit corneal neovascularization models; it also reduced intraocular pressure in acute and chronic glaucoma models after subconjunctival administration 42308467Jun. This work highlighted the feasibility of combining antiangiogenic and pressure-lowering mechanisms in a single agent for ocular neovascular disease 42308467Jun.

Clinical and translational studies also placed VEGFR2-targeted therapy within broader treatment strategies. In renal cell carcinoma, VEGFR kinase inhibitors were discussed in the context of response and adaptation, with SPP1+ tumor-associated macrophages identified as key players in therapy response and chronic treatment associated with metastatic spread 42442342Jul. A cluster randomized trial evaluated the feasibility and safety of intensive versus usual systolic blood pressure control in patients with renal cell or thyroid cancer starting VEGFR tyrosine kinase inhibitors 42158981May, while cabozantinib was assessed in patients with brain metastases from renal cell carcinoma 41946178Apr. In another renal cancer-focused publication, casdatifan, a HIF-2α inhibitor, showed promising activity alone and in combination with the VEGFR TKI cabozantinib, and is being studied further in phase 3 42246926Jun. Fruquintinib, a selective VEGFR-1/2/3 inhibitor, was also incorporated into the design of a phase III trial in pre-treated metastatic gastro-oesophageal adenocarcinoma 42108156May.

VEGFR2 was additionally identified in multi-target and systems-level studies. In ovarian cancer, the KDR gene, which encodes VEGFR2, was among experimentally validated hub genes associated with treatment response and prognosis in a multi-omics machine learning framework 42443519Jul. In triple-negative breast cancer and lung cancer, KDR appeared among core targets in network pharmacology and graph-attention-guided virtual screening studies, supporting its continued relevance in multi-target anticancer discovery 42220063Jun42149884May.

What Changes, What Holds

1. VEGFR2 remains a validated drug target, but the new chemistry mainly extends rather than revises its role
REINFORCES New inhibitor series and supporting docking/ADMET work strengthen the established view of KDR/VEGFR2 as a tractable antiangiogenic oncology target 42208487May41936795Apr. The main change is not conceptual but practical: the recent studies broaden the medicinal chemistry space around VEGFR2 and show that several scaffolds can still match or exceed reference activity in preclinical models. That supports continued target-centric drug discovery rather than altering the baseline account.

2. VEGFR2 is now being used in ocular disease as part of a dual-mechanism strategy
NEW DIRECTION H24 extends the baseline beyond tumor angiogenesis by placing VEGFR2 inhibition into neovascular glaucoma, where the therapeutic logic combines antiangiogenesis with intraocular pressure lowering 42308467Jun. That does not contradict the established oncology-centered role, but it does add a distinct translational use case the Overview does not cover. The work suggests VEGFR2 can be embedded in multi-target ocular therapy, though the broader clinical durability and selectivity of this approach remain unsettled.

3. VEGFR2-targeted therapy is being framed more as an adaptive treatment system than a simple antiangiogenic intervention
REINFORCES The renal cancer and trial reports do not change what VEGFR2 inhibitors are, but they sharpen how they are used: as part of a treatment ecosystem shaped by resistance, blood-pressure management, brain metastasis care, and combination strategies 42442342Jul42158981May. Fruquintinib and cabozantinib remain consistent with the baseline’s oncology focus, while the added translational work mainly refines supportive care and sequencing questions rather than revising VEGFR2 biology.

4. KDR is increasingly treated as a cross-cancer network marker, not only a direct angiogenesis target
NEW DIRECTION Multi-omics and network-screening studies place the KDR gene in prognostic and hub-gene frameworks for ovarian, triple-negative breast, and lung cancer, which goes beyond the Overview’s emphasis on endothelial signaling and antiangiogenic therapy 42443519Jul42220063Jun. The baseline does not discuss this systems-level biomarker role, so this is an added layer of interpretation rather than a contradiction. It suggests KDR may be useful in discovery and stratification contexts, but that remains computational and needs clinical validation.

Overview update candidates: ocular neovascular disease use of VEGFR2-targeted dual inhibitors; systems-level/prognostic framing of KDR in multi-omics and network studies.